Sea Dragon – Market Update

28 July 2015. Link here. SeaDragon Limited (NZX:SEA) today releases an update to the market detailing the company’s progress towards completing the Omega-3 production plant. The update also includes an overview of; • Key products • Customers • The rationale for investment in SeaDragon • The use of proceeds • Financial forecasts • Sustainability statement For […]

Adherium & AstraZeneca Partner to Improve the Lives of Individuals with Respiratory Disease

23 July 2015. Link here. First-in-class collaboration combining digital health with class leading inhaled medications Long term international supply agreement targeted at AstraZeneca’s patient support programs Adherium’s Smartinhaler proven to substantially improve medication adherence and health outcomes in adults and children New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader […]

Avita Medical Shareholder Update

22 July 2015 – link here. Letter from the CEO.

Rex Bionics plc – Announcement of partnership agreement with MAAB

20 July 2015, link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users, is pleased to announce that it has today signed a new agreement for a partnership in China with MAAB Group, an investment and trading company that specialises in sourcing and introducing innovative […]

Avita Medical Announces Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year 2015

20 July 2015 – Link here.

Nexvet and Zenoaq Enter Research and Development Collaboration

DUBLIN, Ireland, July 7, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the signing of a research and development agreement with leading Japanese animal health company Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.) to develop a number of therapeutic biologics for companion animals. The biologics will target undisclosed proteins involved […]

Avita Medical – Data Demonstrating ReCell® Effectiveness in Skin Repigmentation Published in Journal of the American Academy of Dermatology

6 July 2015. Link here for ASX announcement. Demonstrates 78% Repigmentation compared to 0% in Control Groups.